ArticleThe Prostate2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionUsing serum metabolomics in Community-Based Participatory Research (CBPR) with underserved populations presents challenges due to the invasive nature of venipuncture, which limits longitudinal sample collection in community settings. In this pilot study, we compared saliva and serum metabolomics in patients with prostate cancer to evaluate saliva's potential in biomarker research and identified metabolic changes associated with androgen deprivation therapy (ADT).
methodsBlood and saliva were collected from 20 eugonadal patients with prostate cancer and 20 patients receiving ADT. Untargeted metabolomics of metabolites was performed, and glucocorticoids were quantified using targeted metabolomics. Data were analyzed using MassHunter, METLIN database, and MetaboAnalyst.
resultsAcross all samples, 1198 metabolites were identified. Comparing ADT to eugonadal serum and integrating fold change (FC > 2 or FC < 0.5) and significance (adjusted p < 0.1), we identified 14 upregulated and 20 downregulated metabolites. Comparing ADT to eugonadal saliva, we identified 14 upregulated and 28 downregulated metabolites. Targeted metabolomics confirmed correlations between serum and salivary cortisol and salivary and serum cortisone (r = 0.61 and 0.62, p < 0.001), underscoring the potential of saliva glucocorticoids as biomarkers for stress-related metabolic alterations and suggesting that saliva reflects the systemic metabolomic profile.
conclusionADT-associated metabolomic changes are detectable in saliva. Targeted analysis suggests that salivary glucocorticoids may serve as biomarkers of metabolism and stress in community-based studies. Our findings support saliva as a non-invasive alternative to serum for biomarker research, facilitating community-based investigations and advancing public health efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.